Auditor issued unmodified opinion on annual standalone results and unmodified conclusion on quarterly review for OneSource Specialty Pharma.
Standalone net profit for FY26 was ₹212.10 million, a significant improvement from ₹200.00 million in FY25.
Company capitalised ₹186.09 million in borrowing costs to CWIP after year-end project assessments.
Board approved a Composite Scheme for amalgamation with Steriscience entities and Brooks Steriscience.